180 related articles for article (PubMed ID: 20971818)
21. [Observation of humoral immunity reconstitution and its relationship with infection after autologous hematopoietic stem cell transplantation for patients with multiple myeloma].
Liu JR; Li J; Shang JJ; Zheng D; Gu JL; Zou WY; Xu DR
Zhonghua Xue Ye Xue Za Zhi; 2013 Apr; 34(4):317-22. PubMed ID: 23668204
[TBL] [Abstract][Full Text] [Related]
22. Immunoglobulin D myeloma: clinical features and outcome in the era of novel agents.
Zagouri F; Kastritis E; Symeonidis AS; Giannakoulas N; Katodritou E; Delimpasi S; Repousis P; Terpos E; Dimopoulos MA;
Eur J Haematol; 2014 Apr; 92(4):308-12. PubMed ID: 24460646
[TBL] [Abstract][Full Text] [Related]
23. Primary plasma cell leukemia and autologous stem cell transplantation.
Drake MB; Iacobelli S; van Biezen A; Morris C; Apperley JF; Niederwieser D; Björkstrand B; Gahrton G;
Haematologica; 2010 May; 95(5):804-9. PubMed ID: 20442444
[TBL] [Abstract][Full Text] [Related]
24. A case of IgD myeloma representing a missed biclonal paraproteinemia or isotype switch in a patient previously diagnosed with IgA-lambda myeloma.
Chepovetsky J; Chari A; Jagannath S; Ramanthan L
Clin Chim Acta; 2013 Oct; 425():233-5. PubMed ID: 23954772
[TBL] [Abstract][Full Text] [Related]
25. Relapse risk after autologous transplantation in patients with newly diagnosed myeloma is not related with infused tumor cell load and the outcome is not improved by CD34+ cell selection: long term follow-up of an EBMT phase III randomized study.
Bourhis JH; Bouko Y; Koscielny S; Bakkus M; Greinix H; Derigs G; Salles G; Feremans W; Apperley J; Samson D; Björkstrand B; Niederwieser D; Gahrton G; Pico JL; Goldschmidt H;
Haematologica; 2007 Aug; 92(8):1083-90. PubMed ID: 17640853
[TBL] [Abstract][Full Text] [Related]
26. Extramedullary progression of multiple myeloma despite concomitant medullary response to multiple combination therapies and autologous transplant: a case report.
Kumar AK; Dakhil C; Teeka Satyan M; Haideri N
J Med Case Rep; 2014 Sep; 8():299. PubMed ID: 25200389
[TBL] [Abstract][Full Text] [Related]
27. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
28. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.
Krishnan A; Pasquini MC; Logan B; Stadtmauer EA; Vesole DH; Alyea E; Antin JH; Comenzo R; Goodman S; Hari P; Laport G; Qazilbash MH; Rowley S; Sahebi F; Somlo G; Vogl DT; Weisdorf D; Ewell M; Wu J; Geller NL; Horowitz MM; Giralt S; Maloney DG;
Lancet Oncol; 2011 Dec; 12(13):1195-203. PubMed ID: 21962393
[TBL] [Abstract][Full Text] [Related]
29. The current status of hematopoietic stem cell transplantation for multiple myeloma.
Bensinger WI
Clin Adv Hematol Oncol; 2004 Jan; 2(1):46-52. PubMed ID: 16163159
[TBL] [Abstract][Full Text] [Related]
30. Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation.
Fenk R; Liese V; Neubauer F; Bruns I; Kondakci M; Balleisen S; Saure C; Schröder T; Haas R; Kobbe G
Leuk Lymphoma; 2011 Aug; 52(8):1455-62. PubMed ID: 21657961
[TBL] [Abstract][Full Text] [Related]
31. Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect.
Alyea E; Weller E; Schlossman R; Canning C; Mauch P; Ng A; Fisher D; Gribben J; Freeman A; Parikh B; Richardson P; Soiffer R; Ritz J; Anderson KC
Bone Marrow Transplant; 2003 Dec; 32(12):1145-51. PubMed ID: 14647268
[TBL] [Abstract][Full Text] [Related]
32. Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network.
Ozaki S; Harada T; Saitoh T; Shimazaki C; Itagaki M; Asaoku H; Kuroda Y; Chou T; Yoshiki Y; Suzuki K; Murakami H; Hayashi K; Mina R; Palumbo A; Shimizu K; ;
Acta Haematol; 2014; 132(2):211-9. PubMed ID: 24662986
[TBL] [Abstract][Full Text] [Related]
33. Non-cryopreserved peripheral blood stem cells autologous transplantation in multiple myeloma: Bicentric study.
Jennane S; Hasnaoui N; Mahtat EM; Merimi F; Bougar S; El Maaroufi H; Belmekki A; Zafad S; Essakalli M; Mikdame M; Doghmi K
Transfus Clin Biol; 2020 Aug; 27(3):152-156. PubMed ID: 32334934
[TBL] [Abstract][Full Text] [Related]
34. Transplantation as salvage therapy for high-risk patients with myeloma in relapse.
Lee CK; Barlogie B; Zangari M; Fassas A; Anaissie E; Morris C; Van Rhee F; Cottler-Fox M; Thertulien R; Muwalla F; Mazher S; Badros A; Tricot G
Bone Marrow Transplant; 2002 Dec; 30(12):873-8. PubMed ID: 12476279
[TBL] [Abstract][Full Text] [Related]
35. Outcome after autologous stem cell transplantation for multiple myeloma in patients with preceding plasma cell disorders.
Kumar SK; Dingli D; Lacy MQ; Dispenzieri A; Hayman SR; Buadi FK; Rajkumar SV; Litzow MR; Gertz MA
Br J Haematol; 2008 Apr; 141(2):205-11. PubMed ID: 18318761
[TBL] [Abstract][Full Text] [Related]
36. Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study.
Gahrton G; Iacobelli S; Björkstrand B; Hegenbart U; Gruber A; Greinix H; Volin L; Narni F; Carella AM; Beksac M; Bosi A; Milone G; Corradini P; Schönland S; Friberg K; van Biezen A; Goldschmidt H; de Witte T; Morris C; Niederwieser D; Garderet L; Kröger N;
Blood; 2013 Jun; 121(25):5055-63. PubMed ID: 23482933
[TBL] [Abstract][Full Text] [Related]
37. Assessing the efficiency of free light chain assay in monitoring patients with multiple myeloma before and after autologous stem cell transplantation along with serum protein electrophoresis and serum protein immunofixation.
Dogaru M; Lazăr V; Coriu D
Roum Arch Microbiol Immunol; 2011; 70(1):15-22. PubMed ID: 21717807
[TBL] [Abstract][Full Text] [Related]
38. Detection of intracellular IgD using flow cytometry could be a novel and supplementary method to diagnose IgD multiple myeloma.
Wang W; Zhang CX; Li ZL; Gong M; Ma YG
BMC Cancer; 2018 Jun; 18(1):650. PubMed ID: 29890944
[TBL] [Abstract][Full Text] [Related]
39. Light Chain Predominant Intact Immunoglobulin Monoclonal Gammopathy Disorders: Shorter Survival in Light Chain Predominant Multiple Myelomas.
Singh G; Xu H
Lab Med; 2021 Jul; 52(4):390-398. PubMed ID: 33180138
[TBL] [Abstract][Full Text] [Related]
40. Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants.
Avet-Loiseau H; Garand R; Lodé L; Harousseau JL; Bataille R;
Blood; 2003 Feb; 101(4):1570-1. PubMed ID: 12393502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
